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 T lymphocytes are a poorly understood class of immune cells that accumulate at sites of 
inflammation due to infection or autoimmunity. Part of the mystery of this T cell subset derives from lack 
of knowledge of ligands that bind to the T cell receptor (TCR) of  T cells. The conditions under which 
these ligands are induced remain ill-defined, but the Budd laboratory has recently reported that dendritic 
cell (DC) necroptosis exposes a previously unreported ligand for the  TCR, leading to activation of  
T cells. Necroptosis is caspase-independent and can be induced via inhibition of caspase-8, leading to 
formation of a complex containing Receptor Interacting Protein Kinase 1 (RIPK1) known as the 
ripoptosome. In this study, we describe a new connection between glycolysis of DC and their susceptibility 
to necroptosis. DC grown with GM-CSF are highly glycolytic and susceptible to necroptosis induced by 
the pan-caspase blocker zVAD.  However we demonstrate that GM-CSF-generated DCs treated with the 
glycolysis inhibitor 2-deoxyglucose are protected against necroptosis by zVAD. We propose that aerobic 
glycolysis is a prerequisite for DC necroptosis and accordingly their ability to activate  T cells. Inhibition 
of glycolysis does not impact caspase activity levels, production of essential cytokines, or production of 
proteins essential for the ripoptosome. Instead, non-glycolytic DC have increased levels of cleaved RIPK, 
which serves as an inhibitor of Ripoptosome formation. It has been established that activation of DC leads 
to increased cellular rates of aerobic glycolysis. It may be that naïve dendritic cells are protected from 
necroptosis by increased cleavage of RIPK in order to prevent unnecessary cell death and the triggered 
activation of a downstream immune response. 
 
 
 Introduction  
Lyme disease is the most common vector-borne illness in North America. In the United States, the 
Center for Disease Control (CDC) reports the incidence of Lyme disease to be 300,000 annual cases. This 
disease has reached epidemic magnitudes in the northeastern United States and it is also prevalent in the 
upper Midwest. However, Lyme disease incidence is gradually spreading to southern and western states. 
Experts attribute this change to forest regrowth, climate change, and spread of deer [1]. The causative 
agent of Lyme disease is the spirochetal pathogen Borrelia burgdorferi, which is transmitted to humans 
via the Ixodes scapularis tick, more commonly known as the deer tick [2, 3]. 
 T cells are a unique cellular lineage functioning at the interface between the adaptive and innate 
immune responses and are often highly lytic against infected cells, transformed cells, and infiltrating 
CD4+ T cells in inflammatory arthritis [4, 5]. Within organs or tissues inflamed by the presence of 
Borrelia burgdorferi, an unusual accumulation of  T lymphocytes occurs [6]. This phenomenon has 
been similarly reported for certain infections of other bacteria, viruses, protozoans and tumors [7, 8], and 
in autoimmune disorders including rheumatoid arthritis [9-12]. Mice lacking  T cells exhibit greater 
bacterial burden, enhanced cardiac inflammation, and an overall reduced adaptive immune response to 
infection with B. burgdorferi [13]. These collective studies indicate that the main function of  T cells is 
likely to protect host tissues from injuries secondary to inflammation of various causes. Thus, it is not 
surprising that  T cells are reported to be reactive to host proteins upregulated or exposed during 
inflammation [14].  Our previous work has further demonstrated that  T cells respond indirectly to B. 
burgdorferi via Toll-like receptor (TLR) 2 activation on monocytes or dendritic cells (DC) [15].  The  
T cells can subsequently promote full activation of DC [16]. B. burgdorferi can also promote cell death 
of macrophages in a TLR2-dependent manner [17].  These findings prompted further research into 
whether activation of  T lymphocytes by B. burgdorferi either requires or is enhanced by cell death of 
DC. 
  Caspase-8 is critical for the survival and proliferation of T lymphocytes [18-22] and specifically 
promotes cell survival by cleaving Receptor Interacting Protein Kinase 1 (RIPK1). Cleaved RIPK1 
inhibits full-length RIPK1 from complexing with FADD and caspase-8 to form the ripoptosome, which 
induces necroptosis [23, 24]. Necroptosis is a recently discovered form of pro-inflammatory, programmed 
cell death that, unlike all other known types of cell death, does not depend on death effector caspase 
activity [25].  The proteins RIPK1 and Mixed Lineage Kinase Domain-Like Protein (MLKL) are required 
for the induction of necroptosis, which can be triggered by interferons, TLR signaling, death receptors, 
intracellular RNA and DNA sensors, and likely other mediators [26]. Recently, our group examined the 
role of caspase activity in the survival of DC and in their ability to activate  T cells [27].  We 
demonstrated that inhibition of caspases induced necroptosis in murine bone marrow-derived DC 
(BMDC) generated with GM-CSF, yet these cells manifested an enhanced ability to activate  T cells, 
even in the absence of B. burgdorferi. Conversely, BMDC generated with GM-CSF + Interleukin(IL)-4 
strongly upregulated expression of c-FLIP, a known stabilizer of caspase-8, which promoted increased 
caspase-8 activity and decreased necroptosis following caspase inhibition. These cells had high survival 
rates, due to the lack of necroptosis, yet demonstrated a considerably reduced ability to activate  T cells.  
The findings support a model under which  T cell ligands are induced or exposed in stressed or 
necroptotic DC (Collins et al. submitted for publication). 
 We initially attributed the lack of necroptosis induced by caspase inhibition in GM-CSF + IL-4-
cultured BMDC to the elevated levels of c-FLIP. However, the results presented herein demonstrate that 
inhibition of glycolysis in GM-CSF-cultivated BMDC renders them resistant to caspase inhibition-
induced necroptosis. Thus, a connection may exist between metabolism and necroptosis that has yet to be 
elucidated. This is fascinating in light of recent studies demonstrating that activation of immune cells 
corresponds with increased aerobic glycolysis, which is necessary to make the precursors of nucleic acids 
and lipids necessary for cell division, and decreased oxidative phosphorylation [28-31]. Identification of 
such a link between metabolism and necroptosis would dramatically expand our knowledge of this form 
of cell death, which has only been characterized in recent years [26]. Furthermore, this study may provide 
new insight into a potential mechanism for exposure of a  T cell ligand by necroptotic DC. Both of these 
potential outcomes have great merit, as there exists limited information surrounding the prominent roles 
that  T cells and necroptotic DC appear to play in the response to infection/autoimmune-generated 
inflammation. A more accurate and complete understanding of this immune mechanism could have an 
impact on the ways we approach a wide variety of diseases and autoimmune states. The connection 
between metabolism and immune response additionally has implications for our understanding of 




Contamination with environmental LPS was minimized during the preparation of buffers and 
regents by using autoclaved and baked (180°C for 4 hours) glassware, disposable plastic ware, and 
pyrogen-free H2O. 
Mice.  
C57BL/6J mice were housed and bred according to protocols approved by the UVM IACUC. 
Mice were used at 8 to 12 weeks of age for harvest of DC and  T cells from spleens, and harvest of 
bone marrow cells. TNF-/- mice were used to assess the role, or lack thereof, that TNF plays in the 
initiation of necroptosis. 
Bone marrow dendritic cells (BMDC).  
The preparation of bone marrow-derived dendritic cells (BMDC) was done according to the 
method of Lutz et. al. [32] using GM-CSF (10 g/ml BioSource International). Cells were used on day 
7.   
Splenic dendritic cell purification.  
Dendritic cells were isolated and disrupted through nylon mesh mesh in RPMI 1640 with 25 mM 
Hepes (MediaTech, Herndon, VA) containing 5% (v/v) bovine calf serum (HyClone, Logan, UT). 
Differentiated dendritic cells were obtained via CD14+ magnetic beads isolation (Miltenyi Biotech) and 
were immediately used for experimentation.  
Splenic  T cell purification and culture.   
The spleen of an C57BL/6 mouse was isolated and disrupted through nylon mesh in RPMI 1640 
with 25 mM Hepes (MediaTech, Herndon, VA) containing 5% (v/v) bovine calf serum (HyClone, 
Logan, UT). Erythrocyte lysis of splenocytes was performed using Geys solution. Magnetic depletion 
was used to remove bead-bound cells. Isolated  T cells were resuspended in complete medium (RPMI 
1640 (Mediatech, Inc., Herndon, VA, USA), 2.5 mg/ml glucose (Sigma, St. Louis, MO), 10 mg/ml 
folate (Invitrogen, Carlsbad, CA), 110 μg/ml pyruvate (Invitrogen), 5 × 10–5 M 2-mercaptoethanol 
(Sigma), 292.3 μg/ml glutamine (Invitrogen), 100 units/ml penicillin-streptomycin (Invitrogen), and 5% 
fetal calf serum).  Purified  T cells were initially activated at a density of 1 x 106 cells/ml by plate-
bound anti-TCR- (10 μg/ml, clone GL-3), and recombinant human IL-2 (50 units/ml, Cetus).  After 2 
days, cells were removed from anti-TCR- stimulation, supplied with fresh medium plus IL-2, and 
returned to culture at a density of 0.5 x 106 cells/ml.  Cells were counted, and daily supplied with fresh 
media containing 50 units/ml IL-2.  At the time of experiments, typically day 7, cultures were routinely 
over 95%  T cells.  
Co-incubation of Dendritic Cells and T lymphocytes.  
Cultures of DC (5 × 105/ml) with αβ T cells (1 × 106/ml) were made in AIM-V medium with 
GM-CSF (800 U/ml) and 10% FBS. To some cultures was added 2-deoxyglucose or rapamycin 
(10ng/ml) at the doses indicated. 24 hours later, B. burgdorferi sonicate (10 μg/ml) (Sigma-
Aldrich),caspase-8 inhibitor zVAD-fmk (MP Biomedical, Santa Ana CA), was added. Cells were 
incubated for 24 h at 37 ̊C with 5% CO2 release. Supernatants were collected for cytokine analysis and 
cells were assessed for viability.  
Cell Viability Assessment.  
Dendritic cells were removed from experimental plates and percent viability was obtained via 
trypan blue staining and a hemocytometer on a light microscope. Results were confirmed via flow 
cytometry. 
Measurement of Caspase Activity. 
 Pan-caspase activity was determined using the Apo-ONE Assay, which measures the cleavage 
of DEVD-rhodamine. Spectrophotometric readings were taken using a Fluorescence reader. 
Measurement of Metabolic Activity.  
Between 3 and 5×105 cells/well were seeded into Seahorse XF24 microplates and incubated at 
37°C for approximately 24 hr. Subsequently, basal oxygen consumption rate (OCAR) and extracellular 
acidification rate (ECAR) were measured by the Seahorse XF24 Flux analyzer. 
Cytokine Analysis.  
A commercial bioplex assay (BD biosciences) was used to analyze supernatant concentration of 
cytokines IL-1β, TNF, IFNg, and IL-10 via the manufacturer’s instructions. Briefly, samples were run 
undiluted or diluted 1:10 in RPMI complete media.  50 l of the magnetic bead working solution was 
added to each well, then 50 l of appropriate samples or standards were then added to wells and 
incubated at room temperature for 30 min at 300 rpm on an IKA MS 3 digital shaker. After three washes 
with 100 l Bio-Plex wash buffer, incubation with 25 l of detection antibody solution was done at 
room temperature for 30 min on the shaker. Following another set of three washes, 50 l of streptavidin-
phycoerythrin (PE) in assay buffer was added to each well and incubated as described for the previous 
step. After an additional three washes, 125 l of Bio-Plex assay buffer was added. Sample data was 
analyzed with Bio-Plex Manager software. 
Flow Cytometry.   
A Live/Dead Fixable Dead Cell Stain kit (Invitrogen) was used as per the manufacturers’ 
instructions to evaluate cell viability via flow cytometry. For direct staining, single cell suspensions (1 x 
106 total cells per staining condition) were washed with cold (4°C) PBS containing 1% (w/v) BSA 
fraction V (Sigma) (PBS/1% BSA), incubated with unconjugated hamster IgG1 (50 g/ml) for 15 min at 
4°C, washed and then incubated with the appropriate antibodies in PBS/1% BSA. After washing, the 
cells were fixed with freshly made 1% (v/v) methanol-free formaldehyde (Ted Pella Inc., Redding, CA) 
in PBS/1% BSA. Flow cytometry was performed on an LSRII (BD Biosciences, San Jose, CA) 
calibrated with compensation beads (BD Biosciences).  Analysis was performed using FlowJo software 
(Tree Star, Inc., Ashland, OR). 
Western Blot. 
 Day 10 DC were lysed in Tris-buffer containing Complete Protease Inhibitor (Roche) and 0.5% 
NP-40 (Roche). Insoluble cell fragments were removed by centrifugation, and the protein concentration 
of the resulting whole cell lysates was determined by Bradford assay (BioRad, Hercules, CA).  Whole 
cell lysates (30 μg per lane) were separated by SDS-PAGE.  After gel electrophoresis, proteins were 
transferred to PVDF membranes (0.2 μm pore size, Bio-Rad), and immunoblots were performed using 
antibodies (1μg/ml) against MLKL (Cell Signaling), RIPK1 (BD Biosciences), and -actin (BD 
biosciences). Membranes were blocked with 4% BSA and developed via x-ray radiography.  
Statistical Analysis.   
Results are expressed as a mean ± SEM and are representative of at least 2 experiments each. 
GraphPad Prism was used for statistical analysis and graphing capabilities. 
 
Results 
Splenic DCs are less susceptible to caspase-inhibition-mediated necroptosis and accordingly display a 
reduced ability to activate  T cells.  
Our group recently reported that BMDC exposed to the pan-caspase inhibitor zVAD undergo 
necroptosis due to inhibition of caspase-8. These necroptotic BMDC augment activation of  T cells. To 
extend these results using cultured DC, fresh DC were isolated from the mouse spleen in order to assess 
whether in vivo-differentiated DC respond to caspase inhibition in the same manner as in vitro-
differentiated BMDC. Surprisingly, splenic DC did not undergo necroptosis following exposure to zVAD 
as did GM-CSF-differentiated BMDC (Figure 1A). Cytokine analysis of supernatants revealed that fresh 
DC also did not activate  T cells, as indicated by a lack of production of the  T cell cytokine IFN 
(Figure 1B). Of note is that splenic DC are visually much smaller than GM-CSF-cultivated BMDC. 
Interestingly, ongoing research in the Budd laboratory has revealed that IL-15-differentiated  T cells 
are less glycolytic than IL-2-differentiated  T cells. In parallel with this, IL-15 T cells are resistant to 
cell death, whereas IL-2 T cells are quite susceptible to cell death.  In-vitro-differentiated BMDC are quite 
glycolytic compared to freshly isolated DC, and as such we wondered whether the cultivated BMDC 
would also be more susceptible to cell death.  
Decreased aerobic glycolysis protects cells BMDC from zVAD-mediated necroptosis.  
To test our hypothesis that the glycolytic state affects the DC response to zVAD-mediated caspase 
inhibition, we used 2-deoxyglucose (2-DG) or rapamycin to decrease cellular glycolysis. 2-DG is a 
competitive inhibitor of glycolysis while rapamycin inhibits glycolysis by targeting mTOR, a master 
regulator of metabolism. In GM-CSF-differentiated BMDC, exposure to 2-DG or rapamycin had a 
protective effect against zVAD-mediated necroptosis (Figure 2A, B). These inhibitors did not affect IL-
4-differentiated BMDC’s innate protection from zVAD-mediated necroptosis (Figure 2A). Exposure to 
2-DG similarly reduced rates of zVAD-mediated necroptosis in human cells (Figure 2C).  
Although our previous work attributes IL-4-differentiated BMDC’s protection from zVAD-
mediated necroptosis to the increased presence of caspase-8 homolog c-FLIP, we wondered if there might 
be an additional explanation. Accordingly, we measured the glycolytic activity of GM-CSF + IL-4-
differentiated versus GM-CSF-differentiated BMDC by an extracellular flux analyzer. Surprisingly 
however, IL-4 differentiated BMDC had basal levels of glycolysis 5-6-fold higher than GM-CSF-
differentiated BMDCs (Figure 3B). 2-DG-treatment of both types of BMDCS effectively reduced levels 
of glycolysis to near undetectable levels, indicating that the lack of change in necroptosis levels observed 
in 2-DG-treated IL-4 BMDC was not due to incomplete inhibition of glycolysis. 
As such, 2-DG effectively decreases levels of aerobic glycolysis in both types of BMDC, and yet 
this change only impacts necroptosis in the GM-SCF-only-differentiated population. We previously 
demonstrated that increased levels of caspase-8 homolog c-FLIP are present in IL-4-treated BMDC. c-
FLIP can inhibit ripoptosome formation by maintaining activated caspase-8, and consequently cleaved 
RIPK1. Accordingly, we wished to further examine how 2-DG or rapamycin confers resistance of BMDC 
to zVAD-mediated necroptosis. A DVED caspase activity assay indicated that zVAD effectively reduced 
caspase activity in GM-CSF-treated BMDC, regardless of differentiation conditions or exposure to 
glycolysis inhibitor (Figure 3A). zVAD inhibited caspase activity in BMDC, regardless of treatment with 
or without glycolysis inhibitor. However, as previously stated, exposure to zVAD did not induce 
necroptosis in 2DG-treated BMDC (Figure 2). This suggests that a factor triggered by aerobic glycolysis 
is necessary for the induction of necroptosis in DC.  
TNF production is not the missing signal required for induction of necroptosis.  
It has been demonstrated in many cell types that inhibiting caspases alone is sufficient to induce 
necroptosis. Our results suggest a “second signal,” one perhaps intrinsically present in cells and linked to 
aerobic glycolysis, also plays a role in the regulation of necroptosis. In some immortalized cells, the 
cytokine TNF, in addition to caspase blockade, is required to induce necroptosis. Furthermore, activated 
DC are highly glycolytic and can produce large amounts of TNF, so we wondered whether inhibition of 
glycolysis might curb production of TNF and decrease necroptosis induction. To test this hypothesis, we 
used BMDC obtained from a TNF-knock out mouse. Addition of zVAD alone was still sufficient to induce 
necroptosis even in the absence of TNF in these BMDC, based on both trypan blue staining and analysis 
by flow cytometry (Figure 4A, B). To ensure that this was not simply the result of redundancy in the 
system, in that another cytokine might also induce necroptosis, we performed an add-back experiment in 
which WT BMDC incubated with 2DG were treated with exogenous TNF. BMDC did not undergo 
necroptosis when exposed to exogenous TNF, indicating that the “second signal” required for necroptosis 
is not TNF as has been reported for some immortalized cells. 
Cleaved RIPK, an inhibitor for ripoptosome formation, is increased in 2DG-treated BMDC. 
 Aerobic glycolysis is important for synthesis of important metabolic intermediates that cells use 
to generate cellular biomass. To determine whether non-glycolytic BMDC were producing crucial 
ripoptosome proteins, we used western blotting to measure levels of RIPK1 and MLKL in BMDC treated 
with or without 2-DG. Levels of full-length RIPK1 and MLKL were similar in all BMDC, regardless of 
treatment with 2-DG. However, 2-DG-treated BMDC expressed increased levels of cleaved RIPK1, which 
acts as an inhibitor of ripoptosome formation (Figure 5). 
 
Discussion 
As necroptosis is a recently discovered pathway of cell death, its mechanism of action and down-
stream effects on the immune system have yet to be fully described. Studies in mouse-models, including 
those in the Budd laboratory, have linked necroptosis to the development of inflammation and implicated 
this cellular pathway in the pathogenesis of inflammatory diseases. Specifically, the Budd laboratory has 
demonstrated that necroptotic DC activate  T cells. These innate-like T cells operate at the intersection 
of the innate and adaptive immune responses and are upregulated during inflammatory diseases such as 
Lyme disease and Rheumatoid Arthritis. The work presented in this study indicates, for the first time, that 
the metabolic state of DC plays a role in the induction of necroptosis. This is especially interesting in light 
of recent reports demonstrating that a hallmark of immune cell activation is a “switch” from oxidative 
phosphorylation to aerobic glycolysis [28-31]. It has been demonstrated in  T lymphocytes [28, 29], 
macrophages and DC [30, 31] that prior to activation, immune cells primarily utilize oxidative 
phosphorylation and fatty acid breakdown to generate energy. Upon activation, they rapidly begin aerobic 
glycolysis in order to generate the metabolites and energy carriers necessary for production of 
inflammatory mediators and cellular biomass, similar to the Warburg Effect documented in cancer cells 
[29, 30]. Activation of DC and the corresponding switch to aerobic glycolysis may be essential for DC 
necroptosis and subsequent activation of  T cells. 
Observations of primary DC resistance to zVAD-mediated necroptosis triggered our initial interest 
in the role of metabolism in the initiation of necroptosis. Given that DC isolated directly from the murine 
spleen are less proliferative than GM-CSF-cultured BMDC, we wondered whether glycolysis levels might 
be the differing factor. When glycolysis was inhibited in primary human DC or murine BMDCs, these 
cells did not undergo necroptosis following caspase inhibition. These data suggest that DC must be 
glycolytic in order to undergo necroptosis. 
Aerobic glycolysis as a pre-requisite for DC necroptosis could ensure that only activated DC 
undergo necroptosis and accordingly activate other members of the immune system, including  T cells. 
DC can become activated through signaling on TLRs, as in the case of infection with B. burgdorferi. 
Signaling through TLRs has been shown to cause an increase in lactic acid production and glucose 
consumption, both indicative of increased glycolysis [33-34]. This transition to glycolysis is absolutely 
essential for full activation of the DC [34, 35]. Necroptosis is a defense mechanism against viral caspase 
inhibitors, which aim to prevent host cells from undergoing caspase-dependent forms of cell death [36, 
37]. Necroptosis also occurs within inflammatory diseases, but the mechanism of caspase-inhibition 
remains unclear [38]. Regardless of whether necroptosis is virally induced or triggered by an inflammatory 
state, it appears that DC must become activated, as characterized by a switch to aerobic glycolysis, in 
order to undergo necroptosis following caspase-inhibition. 
Previously, we determined that the presence of caspase-8 homolog, c-FLIP, is present at much 
higher levels in IL-4-generated BMDC. Caspase-8 cleaves RIPK1, which inhibits formation of the 
ripoptosome. c-FLIP both stabilizes caspase-8 activation, as well as limits the substrates that can gain 
access to the enzymatic pocket of caspase-8, including the exclusion of zVAD [27]. Interestingly, GM-
CSF + IL-4-grown BMDC are much more glycolytic than GM-CSF-only-cultivated BMDC. These data 
suggest that IL4-grown BMDC may be primarily resistant to necroptosis due to c-FLIP upregulation, 
which appears separate from the mechanism of resistance conferred by low aerobic glycolysis. Current 
research efforts aimed at quantitating c-FLIP levels in 2-DG treated BMDCs will provide additional 
information in the near future. 
The mechanism by which decreased aerobic glycolysis prevents induction of necroptosis remains 
elusive, but our data demonstrate that the connection exists in both human DC and murine BMDC. Low 
glycolysis does not impact the ability of zVAD to inhibit caspase activity, nor is low glycolysis preventing 
production of TNF. Addition of exogenous TNF cannot “rescue” the necroptotic capabilities of non-
glycolytic BMDC, and TNF-/- BMDC undergo necroptosis by zVAD as readily as wild-type BMDC. Non-
glycolytic DC also produce levels of ripoptosome proteins RIPK and MLKL comparable to those 
produced by glycolytic DC. 
A crucial step in the formation of the ripoptosome, and subsequent induction of necroptosis, is 
dimerization of RIPK1 and RIPK3 [39]. Caspase-8 can prevent dimerization by cleaving RIPK1 in its 
intermediate domain, separating its active kinase domain and its death domain. Cleaved RIPK1 
subsequently acts as an inhibitor of full-length RIPK1 [40].  Interestingly, even with inhibited levels of 
caspase-8, non-glycolytic BMDC still express increased cleaved RIPK1. 
These data suggest that naïve, non-glycolytic DC might prevent unnecessary necroptosis and 
subsequent activation of downstream immune responses via cleaved RIPK1. Upon activation, glycolytic 
DC express lower levels of cleaved RIPK1, and accordingly necroptosis is induced following caspase 
inhibition. In the future, measurements of glycolysis and cleaved RIPK1 in naïve DC will provide a clearer 
picture of this phenomenon. 
This study has already indicated an interesting and previously unreported connection between 
necroptosis and aerobic glycolysis, demonstrating that activation of DC may be driving a crucial signal 
for conferring susceptibility to necroptosis. Continued research on this topic will expand our currently 
limited understanding of how DC necroptosis is influenced by cell metabolism, and how cell death can 
lead to activation of the immune response. Increased understanding of the connection between metabolism 
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Figure 1. Freshly isolated splenic DC are less susceptible to caspase-inhibition-mediated necroptosis 
than cultured BMDC and accordingly display a reduce ability to activate  T cells. (A) Cell death 
assessed by trypan blue staining revealed that fresh splenic DC did not die following treatment with 50 
M caspase-inhibitor zVAD, unlike their BMDC counterparts that were differentiated with GMCSF in 
vitro. (B) Cytokine analysis of supernatants indicates that zVAD-treated splenic DCs do not successfully 
activate  T cells. IFN serves as an indicator of  T cell activation as it is not produced by DCs or 
inactive  T cells. Bars: Black:  T cells, Grey: DC; White: /DC co-incubated. All graphs are 
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Figure 2. Reduction of glycolysis in GM-CSF-cultivated DC prevents zVAD-mediated necroptosis. (A) 
BMDC grown with GM-CSF alone or GM-CSF + IL-4 were exposed to 0-10mM 2DG or 10 ng/ml 
rapamycin for 24 hours prior to treatment with 50 M zVAD. Cell death was assessed via trypan blue 
staining. (B) BMDC grown with GMCSF were exposed to 2DG as described in A. Cell death was 
assessed via flow cytometry. (C) Human DCs were isolated from human blood and prepared as 
described in A with exposure to 10 mM 2DG.  
A. 
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Figure 3. Reduced sensitivity to zVAD in DC treated with 2DG is not due to issues in zVAD or 2DG 
efficacy. (A) BMDCs were exposed to 2DG for 24 hours prior to treatment with zVAD. 24 hours later a 
DVED caspase activity assay measured total caspase activity present in equal numbers of viable cells 
from each sample. Results are representative of two independent trials. (B) Glycolysis as reflected in 
lactate production and extracellular acidification rate (ECAR). Measurements made in GM-CSF alone 
versus and GM-CSF + IL-4-differentiated BMDC based on an extracellular flux analyzer. 
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Figure 4. Reduced sensitivity to zVAD in DC treated with 2DG is not due to cells’ inability to produce 
TNF, as it is in some immortalized cell lines. (A) BMDCs from a TNF knock-out mouse were 
differentiated from bone marrow precursors in vitro using GM-CSF alongside WT BMDCs. Both cell 
populations were exposed to 10mM 2DG for 24 hours prior to treatment with 50M zVAD. 24 hours 
later, cell death was assessed using trypan blue staining or in (B) via flow cytometry. (C) BMDCs were 
prepared as described previously, but 0 or 10ng/ml exogenous TNF was added at the time of 50M 
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Figure 5. Levels of cleaved RIPK increase with 2DG-treatment of BMDCs. GM-CSF-differentiated 
BMDCs were treated with or without 2DG for 24 hours prior to treatment with or without zVAD. 
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